SOLID TUMORS

This early-phase trial tested a new drug called TdCyd in 27 adults with advanced solid tumors that had stopped responding to standard treatments. The drug is designed to turn back on genes that may slow tumor growth. The main goal was to find a safe dose and check for side effect…

This study tested a drug called bemarituzumab in 260 adults with solid tumors that have high levels of a protein called FGFR2b. The main goals were to see if the drug is safe and if it can shrink tumors. Participants had already tried other treatments without success.

This early-stage study tested the drug revumenib in 42 adults with colorectal cancer or other solid tumors that had spread or come back after at least one prior treatment. The goal was to see if the drug is safe and can slow tumor growth. Researchers measured side effects, how th…

This early-phase study tested an experimental drug (MK-1454) injected directly into tumors, either alone or with pembrolizumab (Keytruda), in 156 people with advanced solid tumors or lymphomas. The main goals were to find the safest dose and check for side effects. The study also…

This early-phase study tested a new combination of immune cells in 9 people with stage IV solid tumors that had stopped responding to standard treatments. The main goal was to check safety and side effects, while also looking at whether the therapy could shrink tumors or control …

This early-phase study tested a combination of two drugs, dasatinib and bevacizumab, in 50 adults with advanced solid tumors that no longer responded to standard treatments. The goal was to find the safest dose and see how the drugs affect the cancer and the body. Participants to…

This study tested an experimental drug called IDX-1197 in 108 adults with solid tumors that have a specific gene change (HRR mutation). The goal was to find a safe dose and see if the drug can shrink tumors. Participants had cancers that stopped responding to standard treatments …

This study tested a new drug called FF-10502-01 in 106 adults with advanced solid tumors or lymphomas that had stopped responding to standard treatments. The goal was to find the safest dose and see if the drug could shrink tumors or slow disease progression. While not a cure, th…

This early-phase study tested whether adding nilotinib (a pill) to paclitaxel (a standard chemo drug) could safely treat advanced solid tumors that had stopped responding to other therapies. 47 adults and children aged 12 and older took part. The goal was to find the safest dose …

This early-phase trial tested a new drug, NEV801, in 78 adults with advanced solid tumors who had no effective standard treatments left. The main goal was to find the safest dose and check for any side effects. Researchers also looked for signs that the drug might shrink tumors.

This early-stage study tested a new type of immune cell therapy (CAR-T cells) designed to attack a protein called ALPP found on some advanced solid tumors. Five patients with tumors that had not responded to standard treatments received the therapy. The main goals were to check f…

This early-phase study tested a new drug called CFT1946 in 89 adults with BRAF V600 mutant solid tumors (like melanoma, lung, or colon cancer). The goal was to find safe doses and see if the drug works alone or with other medicines (trametinib or cetuximab). Researchers monitored…

This early-phase study tested a new drug called RS-0139 in 16 adults with advanced solid tumors that had come back or spread. The main goals were to find the best dose and check for safety. The drug is designed to target tumors more precisely, but this trial was too small to dete…

This early-phase study tested whether immune cells called natural killer (NK) cells could be safely given to children and young adults with solid tumors that did not respond to standard treatments. Sixteen participants received their own activated NK cells, with or without an imm…

This early-phase study tested a new drug called DF6002, alone or combined with the immunotherapy nivolumab, in 170 adults with advanced solid tumors that had stopped responding to standard treatments. The main goals were to check safety, find the right dose, and see if the drugs …

This study looked at whether taking statins (cholesterol-lowering drugs) can reduce hearing loss caused by platinum-based chemotherapy in people with solid tumors. 56 adults who were about to start chemotherapy took part. The goal was to see if statins could protect their ears fr…

This study watched 225 people with solid tumors who got a drug called G-CSF during chemotherapy. G-CSF can cause bone pain. Researchers measured pain levels and tracked what treatments (like pain relievers or other methods) helped. They also checked quality of life, fatigue, mood…

This study in France looked at how satisfied cancer patients were when they switched from getting immunotherapy at the hospital to getting it at home. It included 49 adults with solid tumors. The goal was to see if home treatment improved their care experience.

This study tested whether iPhones and Apple Watches can reliably collect health data from people with cancer. 49 adults undergoing cancer treatment wore an Apple Watch and used an iPhone for 4 months to track activity, fatigue, and thinking skills. The goal was to see if these de…

This study looked at how the cancer drug belinostat is processed in the body by people with advanced solid tumors or blood cancers. Researchers wanted to see if a person's genetic makeup (specifically the UGT1A1 gene) changes how the drug works or causes side effects. The study i…

This study tested tumor tissue from 470 people with solid tumors to look for specific biomarkers. The goal was to see if those biomarkers could help match participants to other Roche clinical trials testing new cancer treatments. The study did not provide treatment itself, but ai…

This study looked at how a new cancer drug (BI 907828) interacts with two other medicines: rifampicin (an antibiotic) and itraconazole (an antifungal). Thirty-three adults with advanced solid tumors who had no other treatment options took BI 907828 alone and then with one of the …

This study tested whether machine learning can analyze facial expressions and voice recordings to measure pain in people with cancer. 83 participants, aged 12 and older, recorded short videos at clinic visits and at home over about 3 months. The goal was to see if this technology…

This study examines how tumors in different metastatic organs respond to immune checkpoint inhibitor (ICB) therapy in real-world clinical practice. ICB therapy helps the immune system recognize and attack cancer cells, but treatment responses may vary depending on where the cance…